Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study
Aim: The present study was planned to clinically determine the effectiveness of colchicine as a monotherapy in oral submucous fibrosis (OSMF) patients. Materials and Methods: Thirty OSMF patients were enrolled in the study and randomly divided into two groups by permuted-block randomization. Group A...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Journal of Indian Academy of Oral Medicine and Radiology |
| Subjects: | |
| Online Access: | http://www.jiaomr.in/article.asp?issn=0972-1363;year=2021;volume=33;issue=3;spage=236;epage=241;aulast=M. |
| _version_ | 1830454048660127744 |
|---|---|
| author | Somisetty V M. Mounika Rakesh K Manne Natarajan Kannan Swapna S Beeraka Prathi V Sarath Kanamarlapudi V Saikiran |
| author_facet | Somisetty V M. Mounika Rakesh K Manne Natarajan Kannan Swapna S Beeraka Prathi V Sarath Kanamarlapudi V Saikiran |
| author_sort | Somisetty V M. Mounika |
| collection | DOAJ |
| description | Aim: The present study was planned to clinically determine the effectiveness of colchicine as a monotherapy in oral submucous fibrosis (OSMF) patients. Materials and Methods: Thirty OSMF patients were enrolled in the study and randomly divided into two groups by permuted-block randomization. Group A: Patients were treated with 0.5 mg colchicine (Goutnil) tablets twice daily for 3 months. Whereas, in Group B, intralesional injection of dexamethasone 2 mL, hyaluronidase 1,500 IU with 2 mL lignocaine HCl biweekly for 4–6 weeks were given. For all the individuals, baseline parameters like mouth opening, buccal mucosal flexibility, burning sensation, and tongue protrusion were recorded and reassessment was done at 1, 3, and 6 months followed by statistical analysis. Results: A significant decrease in the Visual Analogue Scale (VAS) score for severity of burning sensation was observed in Group A whereas mouth opening and tongue protrusion were higher in Group B patients. Statistically significant differences in the buccal mucosal flexibility were appreciable in the intragroup comparisons of both the groups from baseline to 6-month follow-up. Conclusion : Colchicine can be suggested as an adjuvant drug for reducing the burning sensation for the OSMF patients in whom steroids are contraindicated. |
| first_indexed | 2024-12-21T09:21:47Z |
| format | Article |
| id | doaj.art-26dd59cc8ea9429aae9c8f97235f35eb |
| institution | Directory Open Access Journal |
| issn | 0972-1363 |
| language | English |
| last_indexed | 2024-12-21T09:21:47Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Indian Academy of Oral Medicine and Radiology |
| spelling | doaj.art-26dd59cc8ea9429aae9c8f97235f35eb2022-12-21T19:09:00ZengWolters Kluwer Medknow PublicationsJournal of Indian Academy of Oral Medicine and Radiology0972-13632021-01-0133323624110.4103/jiaomr.jiaomr_108_21Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical studySomisetty V M. MounikaRakesh K ManneNatarajan KannanSwapna S BeerakaPrathi V SarathKanamarlapudi V SaikiranAim: The present study was planned to clinically determine the effectiveness of colchicine as a monotherapy in oral submucous fibrosis (OSMF) patients. Materials and Methods: Thirty OSMF patients were enrolled in the study and randomly divided into two groups by permuted-block randomization. Group A: Patients were treated with 0.5 mg colchicine (Goutnil) tablets twice daily for 3 months. Whereas, in Group B, intralesional injection of dexamethasone 2 mL, hyaluronidase 1,500 IU with 2 mL lignocaine HCl biweekly for 4–6 weeks were given. For all the individuals, baseline parameters like mouth opening, buccal mucosal flexibility, burning sensation, and tongue protrusion were recorded and reassessment was done at 1, 3, and 6 months followed by statistical analysis. Results: A significant decrease in the Visual Analogue Scale (VAS) score for severity of burning sensation was observed in Group A whereas mouth opening and tongue protrusion were higher in Group B patients. Statistically significant differences in the buccal mucosal flexibility were appreciable in the intragroup comparisons of both the groups from baseline to 6-month follow-up. Conclusion : Colchicine can be suggested as an adjuvant drug for reducing the burning sensation for the OSMF patients in whom steroids are contraindicated.http://www.jiaomr.in/article.asp?issn=0972-1363;year=2021;volume=33;issue=3;spage=236;epage=241;aulast=M.colchicinedexamethasonehyaluronidaseintralesional injectionsoral submucous fibrosis |
| spellingShingle | Somisetty V M. Mounika Rakesh K Manne Natarajan Kannan Swapna S Beeraka Prathi V Sarath Kanamarlapudi V Saikiran Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study Journal of Indian Academy of Oral Medicine and Radiology colchicine dexamethasone hyaluronidase intralesional injections oral submucous fibrosis |
| title | Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study |
| title_full | Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study |
| title_fullStr | Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study |
| title_full_unstemmed | Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study |
| title_short | Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study |
| title_sort | colchicine as a therapeutic drug in the management of oral submucous fibrosis a randomized clinical study |
| topic | colchicine dexamethasone hyaluronidase intralesional injections oral submucous fibrosis |
| url | http://www.jiaomr.in/article.asp?issn=0972-1363;year=2021;volume=33;issue=3;spage=236;epage=241;aulast=M. |
| work_keys_str_mv | AT somisettyvmmounika colchicineasatherapeuticdruginthemanagementoforalsubmucousfibrosisarandomizedclinicalstudy AT rakeshkmanne colchicineasatherapeuticdruginthemanagementoforalsubmucousfibrosisarandomizedclinicalstudy AT natarajankannan colchicineasatherapeuticdruginthemanagementoforalsubmucousfibrosisarandomizedclinicalstudy AT swapnasbeeraka colchicineasatherapeuticdruginthemanagementoforalsubmucousfibrosisarandomizedclinicalstudy AT prathivsarath colchicineasatherapeuticdruginthemanagementoforalsubmucousfibrosisarandomizedclinicalstudy AT kanamarlapudivsaikiran colchicineasatherapeuticdruginthemanagementoforalsubmucousfibrosisarandomizedclinicalstudy |